{
    "nctId": "NCT02630628",
    "officialTitle": "A Randomized Open-label Study to Evaluate the Efficacy and Safety of Tacrolimus and Corticosteroids in Comparison With Mycophenolate Mofetil and Corticosteroids in Subjects With Class III/IV\u00b1V Lupus Nephritis",
    "inclusionCriteria": "1. Biopsy-proven LN Class III/IV\u00b1V (ISN/RPS 2003), with biopsy performed within 12 weeks of randomization.\n2. Positive anti-dsDNA.\n3. Active LN with proteinuria (urine protein/creatinine ratio \\>1.0 or 24-hr urine protein \\>1.0 g at baseline), with or without hematuria.\n4. Both 'incident' (i.e. new) patients and 'flare' patients can be included.\n* Must have minimum age of 18 Years",
    "exclusionCriteria": "1. Renal disease unrelated to SLE (e.g. diabetes mellitus, other glomerular or tubulointerstitial disease, renovascular disease), or transplanted kidney.\n2. Estimated glomerular filtration rate (eGFR by MDRD) \u226420 mL/min per 1.73 m2 or serum creatinine \\>300 micromol/L (3.39 mg/dL) at screening.\n3. Renal biopsy showing cellular or fibrocellular crescent in more than 25% of glomeruli.\n4. CNS or other severe organ manifestation of lupus that necessitate aggressive immunosuppressive therapy on its own.\n5. Co-morbidities that require corticosteroid therapy (e.g. asthma, inflammatory bowel disease).\n6. Treatment with prednisolone (or prednisone, or equivalent) at \\>20 mg/D for over 4 weeks within the past 3 months.\n7. Treatment with MMF at \\>1.5 g/D for over 4 weeks within the past 3 months.\n8. Known hypersensitivity or intolerability to prednisolone (or prednisone, or equivalent), TAC, or MMF at a dose of 1.25 g or below per day.\n9. Subjects who are already on treatment with TAC, cyclosporine or any other calcineurin inhibitor for over 4 weeks within the past 12 months.\n10. Treatment with cyclophosphamide, leflunomide, or methotrexate for over 2 weeks, or use of biological agent(s) regardless of duration, within the past 6 months (Note: prior use of azathioprine, mizoribine, intravenous immunoglobulins and anti-malarials is allowed).\n11. Uncontrolled hypertension with systolic BP \\>160 mmHg or diastolic BP \\>95 mmHg.\n12. Women who are pregnant or breastfeeding.\n13. Women with childbearing potential or their male partners, who refuse to use an effective birth control method"
}